JP2021521128A5 - - Google Patents

Info

Publication number
JP2021521128A5
JP2021521128A5 JP2020555164A JP2020555164A JP2021521128A5 JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5 JP 2020555164 A JP2020555164 A JP 2020555164A JP 2020555164 A JP2020555164 A JP 2020555164A JP 2021521128 A5 JP2021521128 A5 JP 2021521128A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
haloalkyl
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521128A (ja
JP7361713B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027992 external-priority patent/WO2019204523A1/en
Publication of JP2021521128A publication Critical patent/JP2021521128A/ja
Publication of JP2021521128A5 publication Critical patent/JP2021521128A5/ja
Application granted granted Critical
Publication of JP7361713B2 publication Critical patent/JP7361713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555164A 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法 Active JP7361713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659068P 2018-04-17 2018-04-17
US62/659,068 2018-04-17
US201862746843P 2018-10-17 2018-10-17
US62/746,843 2018-10-17
PCT/US2019/027992 WO2019204523A1 (en) 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021521128A JP2021521128A (ja) 2021-08-26
JP2021521128A5 true JP2021521128A5 (cg-RX-API-DMAC7.html) 2022-04-11
JP7361713B2 JP7361713B2 (ja) 2023-10-16

Family

ID=66625250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555164A Active JP7361713B2 (ja) 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法

Country Status (13)

Country Link
US (5) US10968201B2 (cg-RX-API-DMAC7.html)
EP (1) EP3781550B1 (cg-RX-API-DMAC7.html)
JP (1) JP7361713B2 (cg-RX-API-DMAC7.html)
KR (1) KR102815312B1 (cg-RX-API-DMAC7.html)
CN (1) CN112313208B (cg-RX-API-DMAC7.html)
AU (2) AU2019255717B2 (cg-RX-API-DMAC7.html)
CA (1) CA3096894A1 (cg-RX-API-DMAC7.html)
DK (1) DK3781550T3 (cg-RX-API-DMAC7.html)
ES (1) ES3010282T3 (cg-RX-API-DMAC7.html)
IL (1) IL277963B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020010879A (cg-RX-API-DMAC7.html)
SG (1) SG11202010153WA (cg-RX-API-DMAC7.html)
WO (1) WO2019204523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195123A1 (en) 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN112313208B (zh) 2018-04-17 2024-04-19 泰普斯特医疗公司 双环羧酰胺及其使用方法
WO2022257960A1 (zh) * 2021-06-08 2022-12-15 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的双环化合物
CN115448882A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN114085167A (zh) * 2021-12-13 2022-02-25 华中药业股份有限公司 一种杂质ts-3a的制备方法
WO2024102968A1 (en) * 2022-11-10 2024-05-16 Tempest Therapeutics, Inc. Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
CN118164967A (zh) * 2022-12-08 2024-06-11 武汉人福创新药物研发中心有限公司 一种ep2、ep4受体拮抗剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2654811A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8934426B2 (en) 2009-04-21 2015-01-13 Apple Inc. Method and apparatus for determining channel quality index in multiple user-MIMO communication networks
WO2010121382A1 (en) 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
WO2011041613A2 (en) 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105451737B (zh) 2013-05-23 2018-04-10 拜耳医药股份有限公司 药物组合物及其用途以及所述药物组合物用于按需避孕的施用方法
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
TWI730032B (zh) * 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物
MX385428B (es) 2016-07-07 2025-03-04 Ono Pharmaceutical Co Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario.
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
WO2018195123A1 (en) * 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN112313208B (zh) 2018-04-17 2024-04-19 泰普斯特医疗公司 双环羧酰胺及其使用方法
CN115448882A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
US20250179017A1 (en) * 2022-02-24 2025-06-05 Guangdong Newopp Biopharmaceuticals Co., Ltd. Carboxamide compounds as pge2 receptor antagonists

Similar Documents

Publication Publication Date Title
JP2020517616A5 (cg-RX-API-DMAC7.html)
DK2958907T3 (en) Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders
JP2007511504A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2022529642A5 (cg-RX-API-DMAC7.html)
JP2022507020A5 (cg-RX-API-DMAC7.html)
JP2019535744A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP2021508686A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
RU2011107278A (ru) Пиримидиновые соединения, композиции и способы применения
JP2019094345A5 (cg-RX-API-DMAC7.html)
JP2017530118A5 (cg-RX-API-DMAC7.html)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2005526857A5 (cg-RX-API-DMAC7.html)
JP2022071077A5 (cg-RX-API-DMAC7.html)
JP2015531764A5 (cg-RX-API-DMAC7.html)
JP2020535124A5 (cg-RX-API-DMAC7.html)
JP2005527542A5 (cg-RX-API-DMAC7.html)
JP2014521609A5 (cg-RX-API-DMAC7.html)
JP2020507625A5 (cg-RX-API-DMAC7.html)
JP2007517007A5 (cg-RX-API-DMAC7.html)